Phase 1 Prostate Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are willing and able to give written consent to participate
- People who have prostate cancer that has spread to other parts of the body (metastatic) and is no longer responding to hormone-reducing treatments, and who are either on ongoing hormone-suppression therapy or have had both testicles surgically removed
- People whose cancer has been difficult to treat or who could not tolerate standard treatments, having already tried at least one hormone-based therapy and a taxane-based chemotherapy at some stage of their advanced disease
- People who are relatively active and able to carry out daily activities, rated 0 or 1 on a standard activity scale (confirm with trial site)
- People who are expected to live for at least 6 months
- People whose liver, kidneys, bone marrow, and other organs are functioning well enough to meet the trial's requirements
Who may not be able to join:
- People who have recently received other anti-cancer drugs, other treatments, major surgery, or radiation therapy within a specific timeframe before joining (confirm with trial site for exact timeframes)
- People currently taking certain medications or herbal supplements that are known to interact with a specific enzyme pathway (CYP3A4) or affect heart rhythm (confirm with trial site for a full list)
- People who still have side effects from previous cancer treatments that have not yet fully resolved
- People with spinal cord compression, cancer that has spread to the brain, or cancer that has spread to the fluid surrounding the brain and spinal cord
- People with serious heart or blood vessel conditions
- People with significant stomach or bowel disorders, or who have had certain stomach or bowel procedures
- People with a history of a hole (perforation) in the stomach or upper small intestine
- People with a history of problems with the pituitary gland
- People with poorly controlled diabetes
- People with an active or uncontrolled condition where the immune system attacks the body
- People with active infections, a known history of HIV, active hepatitis B or C, or active tuberculosis
- People who have had another cancer requiring treatment within the 3 years before starting the study drug
- People with a known allergy or sensitivity to any ingredient in the study drug ACE-232
- People with other medical conditions that, in the treating doctor's judgement, could interfere with the safety of the trial, the accuracy of results, or the person's ability to follow the treatment plan
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 86-18983021726
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of patients experiencing adverse events (AEs)/serious adverse events (SAEs); Number of patients experiencing dose limiting toxicity (DLT), as defined in the protocol; Recommended Phase 2 dose (RP2D) and/or maximum tolerated dose (MTD)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.